Increased IFNGR through Hsp90 inhibition suggests that simultaneous treatment with both an Hsp90 inhibitor and IFN-γ may have a synergistic effect on MHC1 expression and could have beneficial anti-tumour effects. Here, HSP90AB1 is linked to neoplasm.